The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Early outcome of a phase I study of interrupted pulse-dosed axitinib combined with FOLFOX or FOLFIRI in refractory metastatic colorectal cancer.
Eric Roeland
No relevant relationships to disclose
Kelly Anne Shimabukuro
No relevant relationships to disclose
Paul Timothy Fanta
No relevant relationships to disclose
Bethany H. Parker
No relevant relationships to disclose
Michael Hwang
No relevant relationships to disclose
Tony R. Reid
No relevant relationships to disclose